MeMed
3 known investors
MeMed develops host-immune response diagnostics that use machine learning to distinguish between bacterial and viral infections, with its FDA-cleared MeMed BV test delivering results in 15 minutes. Its MeMed Key immunoassay platform runs sensitive multiplexed protein measurements at the point of care to help physicians manage acute infections and reduce unnecessary antibiotic use.</parameter> <parameter name="founders">[]